文献速递心境障碍

活性Alpha-Stim AID与假Alpha-Stim AID在英格兰基层医疗重性抑郁中的临床疗效:Alpha-Stim-D多中心随机对照试验

Clinical effectiveness of active Alpha-Stim AID versus sham Alpha-Stim AID in major depression in primary care in England (Alpha-Stim-D): a multicentre, parallel group, double-blind, randomised controlled trial.
PubMed 文献 · Lancet Psychiatry · 2023-01-29

Alpha-Stim-D试验在英格兰25个基层医疗中心纳入236例正在服用抗抑郁药的重性抑郁患者,随机分入活性(100 μA)或假Alpha-Stim AID组,每日使用1小时共8周。结论:活性Alpha-Stim AID安全可接受,但疗效不优于假装置。

要点

  • 活性Alpha-Stim AID在改善重性抑郁症状方面不优于假装置。
  • 不良事件发生率低,活性组9例(8%)、假组8例(7%)报告不良事件。

核心结论

  • 活性Alpha-Stim AID治疗重性抑郁安全且可接受,但临床疗效不优于假Alpha-Stim AID。

研究设计与样本

  • 多中心、平行组、双盲、随机对照试验,从英格兰两个地区25个基层医疗中心招募参与者。
  • 纳入年龄≥16岁、当前诊断为原发性重性抑郁、PHQ-9评分10-19分、且在过去3个月内已服用抗抑郁药至少6周者。
  • 随机分配(1:1,按地区、焦虑障碍和抗抑郁药使用最小化)至每日1小时活性(100 μA)或假Alpha-Stim AID治疗8周,共236例(每组118例)。
  • 主要结局为随机化后16周时17项汉密尔顿抑郁量表(GRID版)评分较基线的变化,采用意向性分析。

主要发现

  • 236例参与者中17例(7%)报告17起不良事件:活性组9例(8%),假组8例(7%)。
  • 假组报告1起严重不良事件(自杀意念导致住院),判定与装置无关。

临床怎么用

  • 对于正在服用抗抑郁药的重性抑郁患者,活性Alpha-Stim AID未显示优于假装置的额外临床获益。
  • 活性Alpha-Stim AID在此试验中安全性和可接受性良好,不良事件发生率低。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Randomised sham-controlled trials of cranial electrostimulation with the Alpha-Stim Anxiety Insomnia and Depression (AID) device have reported improved anxiety and depression symptoms; however, no adequately powered sham-controlled trials in major depression are available. We investigated whether active Alpha-Stim AID is superior to sham Alpha-Stim AID in terms of clinical effectiveness for depression symptoms in major depression. METHODS: The Alpha-Stim-D trial was a multicentre, parallel group, double-blind, randomised controlled trial, recruiting participants from 25 primary care centres in two regions in England, UK. Eligible participants were aged 16 years or older with a current diagnosis of primary major depression, a score of 10-19 on the nine-item Patient Health Questionnaire, and had been offered or prescribed and reported taking antidepressant medication for at least 6 weeks in the previous 3 months. Main exclusion criteria were contraindications to Alpha-Stim AID device use, having persistent suicidal ideation or self-harm, neurological conditions, a substance use disorder or dependence, an eating disorder, bipolar disorder, or non-affective psychosis, or receiving psychological treatment in the past 3 months. Eligible participants were randomly assigned (1:1, minimised by region, anxiety disorder, and antidepressant use) to 1 h daily use of active (100 μA) or sham Alpha-Stim AID treatment for 8 weeks. Randomisation was via an independent web-based system, with participants, outcome assessors, and data analyst masked to treatment assignment. The primary outcome was change from baseline in score on the 17-item Hamilton Depression Rating Scale (HDRS-17, GRID version) at 16 weeks after randomisation, with participants analysed by intention to treat (ITT; all randomly assigned participants). Safety was assessed in all randomly assigned participants. The trial is registered with the ISRCTN registry (ISRCTN11853110); status completed. FINDINGS: Between Sept 8, 2020, and Jan 14, 2022, 236 eligible participants were randomly assigned to active or sham Alpha-Stim AID (n=118 each). 156 (66%) participants were women, 77 (33%) were men, and three (1%) self-reported as other gender; 200 (85%) were White British or Irish; and the mean age was 38·0 years (SD 15·3; range 16-83). 102 (86%) participants in the active Alpha-Stim AID group and 98 (83%) in the sham group were followed up 16 weeks after randomisation. In the ITT population, mean change in GRID-HDRS-17 at 16 weeks was -5·9 (95% CI -7·1 to -4·8) in the active Alpha-Stim AID group and -6·5 (-7·7 to -5·4) in the sham group (mean change difference -0·6 [95% CI -1·0 to 2·2], p=0·46). Among the 236 participants, 17 adverse events were reported in 17 (7%) participants (nine [8%] participants in the active Alpha-Stim AID group; and eight [7%] participants in the sham group). One serious adverse event of suicidal ideation leading to hospitalisation was reported in the sham group, which was judged to be unrelated to the device. INTERPRETATION: Active Alpha-Stim AID was safe and acceptable, but no more clinically effective than sham Alpha-Stim AID in major depression. FUNDING: National Institute for Health Research Applied Research Collaboration East Midlands and Electromedical Products International.

来源:Lancet Psychiatry,查看原文。版权归原作者所有。

引用

  1. Morriss R, Patel S, Boutry C, et al. Clinical effectiveness of active Alpha-Stim AID versus sham Alpha-Stim AID in major depression in primary care in England (Alpha-Stim-D): a multicentre, parallel group, double-blind, randomised controlled trial. Lancet Psychiatry. 2023. PMID: 36724796. doi:10.1016/S2215-0366(23)00007-X

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。